Investors in BioNTech shares are in a phase of uncertainty. The reason for this is a complex dispute with Moderna over the innovative mRNA vaccine technology. While Moderna accuses the two partners Pfizer and BioNTech of patent infringement, the two counter with a request to lift the contested patents in the USA. Their argument is that Moderna’s patents are not only far-reaching, but also vague.
BioNTech shares could feel the effects of this legal dispute, even though Moderna has not yet made any public comment.
What do price averages say about the BioNTech stock?
Sollten Anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei BioNTech?
BioNTech stock is going through a volatile phase, as a technical analysis shows. The long-term 200-day moving average (GD200) is declining and BioNTech stock is currently trading below it – a scenario that is very bearish in experience. In contrast, BioNTech shares are above the medium-term 100-day average (GD100), which is also falling. This could be interpreted as a bullish sign. Additional optimism is provided by BioNTech stock’s uptrending 38-day moving average (GD38). Bulls are working on a trend reversal!
Important data of BioNTech shares: Overview
- Price: 121 USD
- GD200: 129 USD (falling)
- 52 wk range: 95 – 189 USD
Sollten Anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei BioNTech?
What could be the development of BioNTech stock?
The overall stock market points to a sideways trend in the BioNTech company, which shows both opportunities and risks. The ongoing patent dispute in particular could lead to further volatility. Investors in the BioNTech share should therefore not only keep an eye on the technical indicators, but also on developments in the legal tug-of-war with Moderna. Bears are still at the helm, but a turnaround is already in progress.
Buy, hold or sell? – Your BioNTech analysis of 30/08 provides the answer:
What are the prospects for BioNTech´s development? Is this stock a safe investment for your money?
The answers to these questions and why you need to act now can be found in the current analysis of BioNTech stock.
Autor
Kaufen, halten oder verkaufen - Ihre BioNTech-Analyse von 27.12. liefert die Antwort:
Wie wird sich BioNTech jetzt weiter entwickeln? Ist ihr Geld in dieser Aktie sicher? Die Antworten auf diese Fragen und warum Sie jetzt handeln müssen, erfahren Sie in der aktuellen Analyse zur BioNTech Aktie
